Palvella Therapeutics (PVLA) Non-Current Debt (2013 - 2014)

Palvella Therapeutics (PVLA) posted quarterly Non-Current Debt of $474.0 for Q3 2014, little changed quarter-over-quarter from $474.0 in Q2 2014.

Palvella Therapeutics (PVLA) Non-Current Debt (2013 - 2014) Analysis & Trends

Palvella Therapeutics (PVLA) has reported Non-Current Debt for 2 consecutive years, with $474.0 the latest figure, recorded in Q3 2014.

In Q3 2014, Non-Current Debt changed N/A year-over-year to $474.0; the TTM figure through Sep 2014 stood at $474.0 (changed N/A YoY), while the FY2014 annual figure was $474.0, changed N/A from the prior year.
Non-Current Debt steadied at $474.0 in Q3 2014 per PVLA's latest filing, from $474.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $1.4 million in Q4 2013 and bottomed at $474.0 in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Palvella Therapeutics	2.25 Bn	1.93 Bn	-	-

Download Data